Attovia Therapeutics (ATTO) announced management participation in three investor conferences scheduled for November 2026, including a fireside chat and individual meetings. The Guggenheim fireside chat is November 10, from 3:30–3:55 PM ET. Management will hold individual meetings at Stifel on November 11 and Jefferies in London on November 16–18. The Guggenheim webcast will be available on Attovia’s investor website, with a replay for approximately 90 days.
Attovia Therapeutics (ATTO) will present four posters on ATTO-1310 and ATTO-2306 at two dermatology conferences in 2026.
At EADV in Vienna, September 30–October 3, two ATTO-1310 posters will cover Phase 1a safety and pharmacology data from healthy adults and research into IL-31 levels across itchy skin diseases. At FCD in Las Vegas, October 8–11, one poster will cover interim Phase 1b ATTO-1310 results in patients with high-itch atopic dermatitis or chronic pruritus, while another will present preclinical ATTO-2306 data. The posters will be available on Attovia's website after each conference.
Attovia Therapeutics (ATTO)/b) will participate in two investor conferences in September 2026.Management will hold 1x1 meetings at Citi’s 2026 Biopharma Back to School Conference on September 10, 2026. The company will also join a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on September 16, 2026, from 10:00 AM to 10:35 AM EST, with a live webcast and 90-day replay available via Attovia’s investor website.
Attovia Therapeutics (ATTO) reported second quarter 2026 results and highlighted clinical and financing milestones for its ATTOBODY-based pipeline.
Lead asset ATTO-1310/b) showed preliminary clinical proof of concept in chronic pruritus and high-itch atopic dermatitis, with rapid, deep itch relief and consistent lesion control after a single dose in a Phase 1b study. Complete Phase 1b data are expected in Q4 2026, and global Phase 2 trials in chronic pruritus of unknown origin and high-itch AD are planned to start in the first half of 2027. IND clearance was received in China for a Phase 1b trial in cholestatic pruritus linked to PBC or PSC.Preclinical programs ATTO-2306 and ATTO-1091 remain in IND-enabling studies, with Phase 1 starts targeted for the first half of 2027, and ATTO-006 is advancing toward candidate nomination by year-end 2026. The company completed an upsized IPO with gross proceeds of approximately $332.4 million, and expects cash, cash equivalents and marketable securities, including roughly $305.4 million in IPO net proceeds, to fund operations into 2030. In Q2 2026, Attovia recorded $0.5 million in collaboration revenue, $18.9 million in R&D expenses, $3.3 million in G&A expenses and a net loss of $20.7 million.
Attovia Therapeutics (Nasdaq: ATTO) closed its upsized initial public offering of 19,550,000 common shares, including the underwriters’ full option for 2,550,000 additional shares, at $17.00 per share. According to Attovia, the offering generated approximately $332.4 million in gross proceeds before underwriting discounts, commissions, and expenses, with all shares sold by the company.
Attovia’s stock began trading on the Nasdaq Global Market on August 5, 2026 under the symbol “ATTO.” Morgan Stanley, Leerink Partners, Citigroup and RBC Capital Markets were joint book‑running managers, and LifeSci Capital acted as passive book‑running manager. The SEC declared the registration statement effective on August 4, 2026.
Attovia Therapeutics (Nasdaq: ATTO), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases, began trading on Nasdaq on August 5, 2026 Beijing time. The IPO was priced at $17.00 per share and opened at $21.00, implying an approximate market capitalization of $904 million.
Founded in 2023, Attovia discovers all its product candidates on its ATTOBODY biologics platform, licensed exclusively worldwide from Alamar Biosciences. The platform supports rapid discovery of mono‑, bi‑ and trispecific biologics. IPO proceeds will mainly fund clinical development of lead candidates ATTO‑1310, ATTO‑2306 and research on ATTO‑1091, alongside other corporate purposes.